Pharmacoeconomic implications of new therapies in sepsis

PharmacoEconomics

Volumn 22, Issue 14, 2004, Pages 895-906

  Wood, Kelly A ^a   Angus, Derek C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; DROTRECOGIN; ETOMIDATE; FLUDROCORTISONE; HYDROCORTISONE; RECOMBINANT PROTEIN;

ADRENAL INSUFFICIENCY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HOSPITAL COST; HOSPITAL INFECTION; HUMAN; INFECTION RATE; MEDICAL CARE; MEDICAL PRACTICE; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; SEPSIS;

EID: 6044241916     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422140-00001     Document Type: Review

References (61)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 Jul; 29 (7): 1303-10
2. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia: United States, 1979-1987. JAMA 1990; 263 (7): 937-8
3. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273 (2): 117-23
4. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997 Jul; 25 (7): 1095-100
5. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002 Aug; 288 (7): 862-71
6. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 Mar; 344 (10): 699-709
7. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001 Nov; 345 (19): 1368-77
8. Health Care Financing Administration. 1995 HCFA provider specific file. Washington, DC: Health Care Financing Administration, 1995
9. Vincent JL, Bihari D, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995; 274: 639-44
10. Haley RW, Culver DH, White JW, et al. The nationwide nosocomial infection rate: a new need for vital statistics. Am J Epidemiol 1985 Feb; 121 (2): 159-67
11. Kollef MH, Sharpless L, Vlasnik J, et al. The impact of nosocomial infections on patient outcomes following cardiac surgery. Chest 1997 Sep; 112 (3): 666-75
12. Linde-Zwirble WT, Cooper LM, Angus DC. An upper estimate of the attributable mortality and cost of severe sepsis in surgical patients. Crit Care 2003 Mar; 7 Suppl. (2): S114-5
13. Weycker D, Akhras KS, Edelsberg J, et al. Long-term mortality and medical-care charges in patients with severe sepsis. Crit Care Med 2003 Sep; 31 (9): 2316-23
14. Matthay MA. Severe sepsis: a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 2001 Mar; 344 (10): 759-62
15. Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000 Feb; 95 (4): 1113-6
16. Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med 2001 Jun; 163 (7): 1520-3
17. Molijn GJ, Spek JJ, van Uffelen JC, et al. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 1995 Jun; 80 (6): 1799-803
18. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995 Jul; 23 (7): 1294-303
19. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995 Aug; 23 (8): 1430-9
20. Brown JM. Corticosteroids for patients with septic shock. JAMA 2003 Jan; 289 (1): 41
21. Schenarts CL, March JA. Corticosteroids for patients with septic shock. JAMA 2003 Jan; 289 (1): 43-4
22. Opal SM. Corticosteroids for patients with septic shock. JAMA 2003 Jan; 289 (1): 43-2
23. Millo J. Corticosteroids for patients with septic shock. JAMA 2003 Jan; 289 (1): 43-4
24. Zijlstra JG, van der Horst I, Tulleken JE, et al. Corticosteroids for patients with septic shock. JAMA 2003 Jan; 289 (1): 42
25. Williamson DR, Albert M, Charneux M. Corticosteroids for patients with septic shock. JAMA 2003 Jan; 289 (1): 43-4
26. Mokhlesi B. Corticosteroids for patients with septic shock. JAMA 2003 Jan; 289 (1): 43-4
27. Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s: systemic inflammatory response and organ dysfunction. JAMA 1994 Jan; 271 (3): 226-33
28. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276 (15): 1253-8
29. Heyland DK, Kernerman P, Gafni A, et al. Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Crit Care Med 1996; 24 (9): 1591-8
30. Angus DC, Rubenfeld GD, Roberts MS, et al. Understanding costs and cost-effectiveness in critical care: report from the Second American Thoracic Society Workshop on Outcomes Research. Am J Respir Crit Care Med 2002 Feb; 165 (4): 540-50
31. Gold MR, Russell LB, Seigel JE, et al. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996
32. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine: panel on cost-effectiveness in health and medicine. JAMA 1996; 276 (14): 1172-7
33. Hadorn DC. Setting health care priorities in Oregon: cost-effectiveness meets the rule of rescue. JAMA 1991 May; 265 (17): 2218-25
34. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis: the Ibuprofen in Sepsis Study Group. N Engl J Med 1997 Mar; 336 (13): 912-8
35. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003 Feb; 348 (8): 683-93
36. Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. JAMA 1997; 277 (13): 1058-63
37. Angus DC, Laterre PF, Helterbrand JD, et al. The effects of drotrecogin alfa (activated) on long-term survival after severe sepsis. Chest 2002 Oct; 122 Suppl. 4: 51S
38. Kaplan V, Clermont G, Griffin MF, et al. Pneumonia: still the old man's friend? Arch Intern Med 2003 Feb; 163 (3): 317-23
39. Chelluri L, Pinsky MR, Donahoe M, et al. Long-term outcome of critically ill elderly patients requiring intensive care. JAMA 1993; 269: 3119-23
40. Angus DC, Musthafa AA, Clermont G, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001 May; 163 (6): 1389-94
41. Clermont G, Angus DC, Linde-Zwirble WT, et al. Does acute organ dysfunction predict patient-centered outcomes? Chest 2002 Jun; 121 (6): 1963-71
42. Angus DC, Carlet J, on behalf of the 2002 Brussels Roundtable Participants. Surviving intensive care: a report from the 2002 Brussels Roundtable. Intensive Care Med 2003 Mar; 29 (3): 368-77
43. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 Apr; 348 (16): 1546-54
44. Angus DC, Wax RS. The epidemiology of sepsis: an update. Crit Care Med 2001 Jul; 29 (7 Suppl.): S109-16
45. Levy MM, Fink M, Marshall JC, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003 Apr; 31 (4): 1250-6
46. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101 (6): 1644-55
47. Xigris: drotrecogin-α [activated]: PV 3420 AMP. Rockville (MD): Food and Drug Administration, 2001
48. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13 (10): 818-29
49. Angus D, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003 Jan; 31 (1): 1-11
50. Manns BJ, Lee H, Doig CJ, et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002 Sep; 347 (13): 993-1000
51. Cariou A, Chiche JD, Charpentier J, et al. The era of genomics: impact on sepsis clinical trial design. Crit Care Med 2002 May; 30 (5 Suppl.): S341-8
52. O'Brien B. Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials? Med Care 1996 Dec; 34 (12 Suppl.): DS99-DS108
53. Clermont G, Linde-Zwirble WT, van Hout BA, et al. The effect of recombinant human activated Protein C on hospital costs and resource use in severe sepsis [abstract]. Am J Respir Crit Care Med 2001 Apr; 163 (5): A802
54. Angus DC, Clermont G, Watson RS, et al. Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics 2003 Dec; 112 (6): 1351-60
55. Howard S, Mugford M, Normand C, et al. A cost-effectiveness analysis of neonatal ECMO using existing evidence. Int J Technol Assess Health Care 1996; 12 (1): 80-92
56. Shorr AF, O'Malley PG. Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia: potential economic implications. Chest 2001 Jan; 119 (1): 228-35
57. Finkler SA, Knickman JR, Hendrickson G, et al. A comparison of work-sampling and time-and-motion techniques for studies in health services research. Health Serv Res 1993 Dec; 28 (5): 577-97
58. Zupancic JA, Richardson DK. Characterization of neonatal personel time inputs and prediction from clinical variables: a time and motion study. J Perinatol 2002 Dec; 22 (8): 658-63
59. Bonneux L, Barendregt JJ, Nusselder WJ, et al. Preventing fatal diseases increases healthcare costs: cause elimination life table approach [published erratum appears in BMJ 1999 Feb 20; 318 (7182): 498]. BMJ 1998 Jan; 316 (7124): 26-9
60. Rubenfeld GD, Angus DC, Pinsky MR, et al. Outcomes research in critical care: results of the American Thoracic Society Critical Care Assembly Workshop on Outcomes Research. Am J Respir Crit Care Med 1999; 160: 358-67
61. Wood KA, Huang D, Angus DC. Improving clinical trial design in acute lung injury. Crit Care Med 2003 Apr; 31 (4): S305-11